Salvage radiotherapy for prostate cancer

References

• Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28:555 - 65; http://dx.doi.org/10.1016/S0094-0143(05)70163-4; PMID: 11590814
   PubMed Web of Science ®Google Scholar
• Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007; 25:110 - 4; http://dx.doi.org/10.1016/j.urolonc.2006.06.003; PMID: 17349524
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181:956 - 62; http://dx.doi.org/10.1016/j.juro.2008.11.032; PMID: 19167731
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al, European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366:572 - 8; http://dx.doi.org/10.1016/S0140-6736(05)67101-2; PMID: 16099293
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27:2924 - 30; http://dx.doi.org/10.1200/JCO.2008.18.9563; PMID: 19433689
   PubMed Web of Science ®Google Scholar
• Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, Trabulsi EJ, et al. Physician Beliefs and Practices for Adjuvant and Salvage Radiation Therapy After Prostatectomy. Int J Radiat Oncol Biol Phys 2012; 82:e233 - 8; http://dx.doi.org/10.1016/j.ijrobp.2011.04.003; PMID: 21605945
   PubMedGoogle Scholar
• Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012; 48:837 - 44; http://dx.doi.org/10.1016/j.ejca.2011.08.013; PMID: 21945099
   PubMed Web of Science ®Google Scholar
• King CR. Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?. Int J Radiat Oncol Biol Phys 2011; 80:1 - 3; http://dx.doi.org/10.1016/j.ijrobp.2010.10.073; PMID: 21277112
   PubMed Web of Science ®Google Scholar
• King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008; 71:23 - 7; http://dx.doi.org/10.1016/j.ijrobp.2007.09.047; PMID: 18207668
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25:2035 - 41; http://dx.doi.org/10.1200/JCO.2006.08.9607; PMID: 17513807
   PubMed Web of Science ®Google Scholar
• Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Strup S, Petersen RO, et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology 1998; 52:1034 - 40; http://dx.doi.org/10.1016/S0090-4295(98)00405-1; PMID: 9836551
   PubMed Web of Science ®Google Scholar
• Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 2011; 60:842 - 9; http://dx.doi.org/10.1016/j.eururo.2011.04.021; PMID: 21514039
   PubMed Web of Science ®Google Scholar
• Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 2011; 60:1142 - 8; http://dx.doi.org/10.1016/j.eururo.2011.08.006; PMID: 21855208
   PubMed Web of Science ®Google Scholar
• Ohri N, Dicker AP, Showalter TN. Reply letter to: Salvage radiotherapy: A plea for dose-escalation with intensity modulated radiotherapy. Eur J Cancer 2012; 48:837 - 44; http://dx.doi.org/10.1016/j.ejca.2011.08.013; PMID: 21945099
   PubMed Web of Science ®Google Scholar
• Sandhu A, Sethi R, Rice R, Wang JZ, Marcus L, Salem C, et al. Prostate bed localization with image-guided approach using on-board imaging: reporting acute toxicity and implications for radiation therapy planning following prostatectomy. Radiother Oncol 2008; 88:20 - 5; http://dx.doi.org/10.1016/j.radonc.2008.05.009; PMID: 18524399
   PubMed Web of Science ®Google Scholar
• Singh AK, Ménard C, Guion P, Simone NL, Smith S, Crouse NS, et al. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. Int J Radiat Oncol Biol Phys 2006; 65:1008 - 13; http://dx.doi.org/10.1016/j.ijrobp.2006.02.030; PMID: 16730138
   PubMed Web of Science ®Google Scholar
• Perrotti M, Doyle T, Kumar P, McLeod D, Badger W, Prater S, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008; 26:276 - 80; http://dx.doi.org/10.1016/j.urolonc.2007.04.003; PMID: 18452819
   PubMed Web of Science ®Google Scholar
• Martini T, Mayr R, Trenti E, Palermo S, Comploj E, Pycha A, et al. The Role of C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases. Adv Urol 2012; 2012:601572; http://dx.doi.org/10.1155/2012/601572; PMID: 21822429
   PubMedGoogle Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-Fractionation Sensitivity of Prostate Cancer Deduced from Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82:e17 - 24; http://dx.doi.org/10.1016/j.ijrobp.2010.10.075; PMID: 21324610
   PubMedGoogle Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:1095 - 101; http://dx.doi.org/10.1016/S0360-3016(98)00438-6; PMID: 10192361
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Jarrard DF, Graf AK, Hedican SP, Paolone DR, Wegenke JD, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 2011; 117:2629 - 36; http://dx.doi.org/10.1002/cncr.25824; PMID: 21656740
   PubMed Web of Science ®Google Scholar
• Lee LW, McBain CA, Swindell R, Wylie JP, Cowan RA, Logue JP. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin Oncol (R Coll Radiol) 2004; 16:517 - 22; http://dx.doi.org/10.1016/j.clon.2004.07.006; PMID: 15630843
   PubMed Web of Science ®Google Scholar
• Niemierko A, Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol 1991; 20:166 - 76; http://dx.doi.org/10.1016/0167-8140(91)90093-V; PMID: 1852908
   PubMed Web of Science ®Google Scholar
• King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol 2011; 43:428 - 37; http://dx.doi.org/10.1159/000322507; PMID: 21625167
   PubMed Web of Science ®Google Scholar
• Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62:679 - 94; http://dx.doi.org/10.1259/0007-1285-62-740-679; PMID: 2670032
   PubMed Web of Science ®Google Scholar